TW201841653A - 以抗-cd52抗體治療多發性硬化症 - Google Patents

以抗-cd52抗體治療多發性硬化症 Download PDF

Info

Publication number
TW201841653A
TW201841653A TW107113566A TW107113566A TW201841653A TW 201841653 A TW201841653 A TW 201841653A TW 107113566 A TW107113566 A TW 107113566A TW 107113566 A TW107113566 A TW 107113566A TW 201841653 A TW201841653 A TW 201841653A
Authority
TW
Taiwan
Prior art keywords
dose
patient
antibody
administered
patients
Prior art date
Application number
TW107113566A
Other languages
English (en)
Chinese (zh)
Inventor
大衛 H 瑪葛林
Original Assignee
美商建新公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商建新公司 filed Critical 美商建新公司
Publication of TW201841653A publication Critical patent/TW201841653A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW107113566A 2017-04-21 2018-04-20 以抗-cd52抗體治療多發性硬化症 TW201841653A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762488630P 2017-04-21 2017-04-21
US62/488,630 2017-04-21
US201762575119P 2017-10-20 2017-10-20
US62/575,119 2017-10-20
US201862647301P 2018-03-23 2018-03-23
US62/647,301 2018-03-23

Publications (1)

Publication Number Publication Date
TW201841653A true TW201841653A (zh) 2018-12-01

Family

ID=62117065

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107113566A TW201841653A (zh) 2017-04-21 2018-04-20 以抗-cd52抗體治療多發性硬化症

Country Status (6)

Country Link
US (2) US20200299399A1 (https=)
EP (1) EP3612564A2 (https=)
JP (2) JP7219721B2 (https=)
CN (1) CN110546167A (https=)
TW (1) TW201841653A (https=)
WO (1) WO2018195457A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
KR101583587B1 (ko) * 2006-09-13 2016-01-08 젠자임 코포레이션 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료
EP2998405B1 (en) * 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
WO2015017690A1 (en) * 2013-08-01 2015-02-05 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy
PT3204425T (pt) * 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados

Also Published As

Publication number Publication date
EP3612564A2 (en) 2020-02-26
WO2018195457A2 (en) 2018-10-25
JP7219721B2 (ja) 2023-02-08
JP2023052642A (ja) 2023-04-11
US20230167189A1 (en) 2023-06-01
WO2018195457A3 (en) 2018-11-29
JP2020517648A (ja) 2020-06-18
US20200299399A1 (en) 2020-09-24
CN110546167A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
CN105188751A (zh) 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法
Johnston et al. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
EP3864053B1 (en) Treatment of rms by switching therapy
WO2024243323A1 (en) Treatment of multiple sclerosis with anti-cd40l antibodies
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
Soelberg Sorensen Intravenous polyclonal human immunoglobulins in multiple sclerosis
TW202222829A (zh) 治療皮膚型紅斑狼瘡及全身性紅斑狼瘡之方法
JP2022502380A (ja) 抗ｃｄ１５４抗体の安全な投与を提供する方法
CA3153634A1 (en) Methods of treatment using omalizumab
Mahdavian et al. Multiple sclerosis: a supplement on the disease state, current therapies, and investigational treatments
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
AU2024287304A1 (en) Compositions and methods for treating multiple sclerosis
HK40051003A (en) Treatment of rms by switching therapy
HK40051003B (en) Treatment of rms by switching therapy
CN117813328A (zh) 用于治疗儿童ms的奥法妥木单抗
Cortese et al. Immunomodulatory Therapy for Multiple Sclerosis
PhilipKinkel High-dose methylprednisolone to treat